Tags

Type your tag names separated by a space and hit enter

APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics.
CNS Neurol Disord Drug Targets 2010; 9(4):395-402CN

Abstract

A critical requirement in the development of Alzheimer's disease (AD) therapeutics is a demonstration of the in vivo efficacy of compounds in pre-clinical disease relevant models. One of the most frequently used models in AD research are transgenic mice overexpressing mutant forms of human amyloid precursor protein (APP) that are associated with early-onset familial AD. These mice exhibit an age-dependent accumulation and deposition of amyloid -peptide (A) as extracellular plaques in the brain, and thereby depict one of the key pathologies observed in the brains of AD patients. Although these mouse models do not recapitulate all the pathological features of AD, they have been invaluable in the development of therapeutic agents aimed at lowering A production, inhibiting A deposition or facilitating A clearance. Further development of these APP transgenic models led to the incorporation of transgenes for human mutant presenilins, resulting in an accelerated A deposition rate and human mutant tau protein leading to neurofibrillary tangle-like pathology. The latter was a major advance in the development of AD models, as it allowed researchers to investigate the interplay between the two key pathologies of AD. This review highlights how APP transgenic mouse models have successfully been used in drug discovery to support the progression of A lowering therapeutics to clinical trials to ultimately test the 'amyloid hypothesis' of AD.

Authors+Show Affiliations

Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, New Frontiers Science Park, Harlow, Essex, UK. ishrut.2.hussain@gsk.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20522015

Citation

Hussain, Ishrut. "APP Transgenic Mouse Models and Their Use in Drug Discovery to Evaluate Amyloid- Lowering Therapeutics." CNS & Neurological Disorders Drug Targets, vol. 9, no. 4, 2010, pp. 395-402.
Hussain I. APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics. CNS Neurol Disord Drug Targets. 2010;9(4):395-402.
Hussain, I. (2010). APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics. CNS & Neurological Disorders Drug Targets, 9(4), pp. 395-402.
Hussain I. APP Transgenic Mouse Models and Their Use in Drug Discovery to Evaluate Amyloid- Lowering Therapeutics. CNS Neurol Disord Drug Targets. 2010;9(4):395-402. PubMed PMID: 20522015.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics. A1 - Hussain,Ishrut, PY - 2009/12/16/received PY - 2010/02/09/accepted PY - 2010/6/5/entrez PY - 2010/6/5/pubmed PY - 2010/11/10/medline SP - 395 EP - 402 JF - CNS & neurological disorders drug targets JO - CNS Neurol Disord Drug Targets VL - 9 IS - 4 N2 - A critical requirement in the development of Alzheimer's disease (AD) therapeutics is a demonstration of the in vivo efficacy of compounds in pre-clinical disease relevant models. One of the most frequently used models in AD research are transgenic mice overexpressing mutant forms of human amyloid precursor protein (APP) that are associated with early-onset familial AD. These mice exhibit an age-dependent accumulation and deposition of amyloid -peptide (A) as extracellular plaques in the brain, and thereby depict one of the key pathologies observed in the brains of AD patients. Although these mouse models do not recapitulate all the pathological features of AD, they have been invaluable in the development of therapeutic agents aimed at lowering A production, inhibiting A deposition or facilitating A clearance. Further development of these APP transgenic models led to the incorporation of transgenes for human mutant presenilins, resulting in an accelerated A deposition rate and human mutant tau protein leading to neurofibrillary tangle-like pathology. The latter was a major advance in the development of AD models, as it allowed researchers to investigate the interplay between the two key pathologies of AD. This review highlights how APP transgenic mouse models have successfully been used in drug discovery to support the progression of A lowering therapeutics to clinical trials to ultimately test the 'amyloid hypothesis' of AD. SN - 1996-3181 UR - https://www.unboundmedicine.com/medline/citation/20522015/APP_transgenic_mouse_models_and_their_use_in_drug_discovery_to_evaluate_amyloid__lowering_therapeutics_ L2 - http://www.eurekaselect.com/93967/article DB - PRIME DP - Unbound Medicine ER -